USPSTF draft backs breast-cancer prevention drugs when risk is high

04/15/2013 | Reuters · DailyRx.com · AAFP News Now

The U.S. Preventive Services Task Force released draft guidelines urging providers to discuss with appropriate female patients the benefits and dangers of drugs that could reduce breast cancer risks. Providers should offer tamoxifen or raloxifene in cases of increased risk of breast cancer and when side effects appear unlikely. "As family physicians, we need to be prepared to have those discussions with our patients, and that means being familiar with risk assessment tools," said USPSTF member Mark Ebell, M.D.

View Full Article in:

Reuters · DailyRx.com · AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY